Todd Brady, Aldeyra Therapeutics CEO
Aldeyra to resubmit dry eye disease drug this year following positive Phase 3 data
Aldeyra Therapeutics plans to make another run at FDA approval for its dry eye disease drug after the agency handed down a complete response letter …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
